Comprehensive Stock Comparison
Compare Royalty Pharma plc (RPRX) vs Vertex Pharmaceuticals Incorporated (VRTX) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth |  VRTX | 8.9% revenue growth vs RPRX's 5.1% |
| Value |  RPRX | Lower P/E (9.7x vs 24.5x) |
| Quality / Margins | RPRX | 32.6% net margin vs VRTX's 31.3% |
| Stability / Safety | RPRX | Beta 0.36 vs VRTX's 0.44 |
| Dividends | RPRX | 1.4% yield; 2-year raise streak; VRTX pays no meaningful dividend |
| Momentum (1Y) | RPRX | +44.5% vs VRTX's -2.5% |
| Efficiency (ROA) | VRTX | 14.8% ROA vs RPRX's 4.0%, ROIC 22.8% vs 6.7% |
Who Each Stock Is For
Income & stability
RPRXDividend streak 2 yrs, beta 0.36, yield 1.4%
Growth exposure
VRTXRev growth 8.9%, EPS growth 8.4%, 3Y rev CAGR 10.4%
Long-term compounding (10Y)
VRTX436.2% 10Y total return vs RPRX's 16.3%
Sleep-well-at-night portfolio
RPRXLower volatility, beta 0.36, Low D/E 91.5%, current ratio 0.97x
Defensive / Recession hedge
RPRXBeta 0.36, yield 1.4%, current ratio 0.97x
Business Model
What each company does and how it makes money
Royalty Pharma is a specialized investment firm that acquires royalty interests in approved and development-stage biopharmaceutical products. It generates revenue primarily from royalty payments on approximately 35 marketed therapies — with its largest assets including cystic fibrosis drug Trikafta and HIV treatment Biktarvy — which provide predictable cash flows. The company's competitive advantage lies in its deep expertise in valuing complex biopharmaceutical royalties and its extensive industry relationships that provide access to proprietary deal flow.
Vertex Pharmaceuticals is a biotechnology company focused on developing and commercializing transformative medicines for serious diseases, with its flagship franchise targeting cystic fibrosis. It generates nearly all its revenue from CF therapies — primarily Trikafta/Kaftrio — while building a pipeline in pain, kidney disease, and type 1 diabetes. Its moat stems from deep scientific expertise in CFTR biology and a dominant, near-monopoly position in the CF treatment market.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
RPRX 3VRTX 2RPRX4/6 metricsRPRX6/6 metricsVRTX9/9 metricsVRTX4/6 metricsRPRX2/2 metricsRPRX leads in 3 of 6 categories (Financial Metrics, Valuation Metrics). VRTX leads in 2 (Profitability & Efficiency, Total Returns).
Financial Metrics (TTM)
VRTX is the larger business by revenue, generating $11.7B annually — 5.0x RPRX's $2.3B. Profitability is closely matched — net margins range from 32.6% (RPRX) to 31.3% (VRTX). On growth, VRTX holds the edge at +11.0% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | RPRXRoyalty Pharma plc | VRTXVertex Pharmaceut… |
|---|---|---|
| RevenueTrailing 12 months | $2.3B | $11.7B |
| EBITDAEarnings before interest/tax | $1.5B | $4.2B |
| Net IncomeAfter-tax profit | $765M | $3.7B |
| Free Cash FlowCash after capex | $2.4B | $3.3B |
| Gross MarginGross profit ÷ Revenue | +100.0% | +86.3% |
| Operating MarginEBIT ÷ Revenue | +65.2% | +34.1% |
| Net MarginNet income ÷ Revenue | +32.6% | +31.3% |
| FCF MarginFCF ÷ Revenue | +102.4% | +28.5% |
| Rev. Growth (YoY)Latest quarter vs prior year | +7.9% | +11.0% |
| EPS Growth (YoY)Latest quarter vs prior year | -44.8% | +4.7% |
Valuation Metrics
At 26.6x trailing earnings, RPRX trades at a 14% valuation discount to VRTX's 30.9x P/E. On an enterprise value basis, RPRX's 9.9x EV/EBITDA is more attractive than VRTX's 25.4x.
| Metric | RPRXRoyalty Pharma plc | VRTXVertex Pharmaceut… |
|---|---|---|
| Market CapShares × price | $7.1B | $120.4B |
| Enterprise ValueMkt cap + debt − cash | $15.4B | $119.0B |
| Trailing P/EPrice ÷ TTM EPS | 26.55x | 30.93x |
| Forward P/EPrice ÷ next-FY EPS est. | 9.72x | 24.47x |
| PEG RatioP/E ÷ EPS growth rate | — | 3.73x |
| EV / EBITDAEnterprise value multiple | 9.89x | 25.38x |
| Price / SalesMarket cap ÷ Revenue | 2.98x | 10.03x |
| Price / BookPrice ÷ Book value/share | 2.73x | 6.55x |
| Price / FCFMarket cap ÷ FCF | 2.85x | 37.68x |
Profitability & Efficiency
VRTX delivers a 21.2% return on equity — every $100 of shareholder capital generates $21 in annual profit, vs $8 for RPRX. VRTX carries lower financial leverage with a 0.20x debt-to-equity ratio, signaling a more conservative balance sheet compared to RPRX's 0.91x. On the Piotroski fundamental quality scale (0–9), VRTX scores 5/9 vs RPRX's 4/9, reflecting solid financial health.
| Metric | RPRXRoyalty Pharma plc | VRTXVertex Pharmaceut… |
|---|---|---|
| ROE (TTM)Return on equity | +8.0% | +21.2% |
| ROA (TTM)Return on assets | +4.0% | +14.8% |
| ROICReturn on invested capital | +6.7% | +22.8% |
| ROCEReturn on capital employed | +8.7% | +23.0% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 5 |
| Debt / EquityFinancial leverage | 0.91x | 0.20x |
| Net DebtTotal debt minus cash | $8.3B | $3.7B |
| Cash & Equiv.Liquid assets | $619M | $5.1B |
| Total DebtShort + long-term debt | $9.0B | $3.7B |
| Interest CoverageEBIT ÷ Interest expense | 5.66x | 348.55x |
Total Returns (with DRIP)
A $10,000 investment in VRTX five years ago would be worth $22,803 today (with dividends reinvested), compared to $12,113 for RPRX. Over the past 12 months, RPRX leads with a +44.5% total return vs VRTX's -2.5%. The 3-year compound annual growth rate (CAGR) favors VRTX at 17.6% vs RPRX's 12.3% — a key indicator of consistent wealth creation.
| Metric | RPRXRoyalty Pharma plc | VRTXVertex Pharmaceut… |
|---|---|---|
| YTD ReturnYear-to-date | +22.2% | +4.8% |
| 1-Year ReturnPast 12 months | +44.5% | -2.5% |
| 3-Year ReturnCumulative with dividends | +41.7% | +62.5% |
| 5-Year ReturnCumulative with dividends | +21.1% | +128.0% |
| 10-Year ReturnCumulative with dividends | +16.3% | +436.2% |
| CAGR (3Y)Annualised 3-year return | +12.3% | +17.6% |
Risk & Volatility
RPRX is the less volatile stock with a 0.36 beta — it tends to amplify market swings less than VRTX's 0.44 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. RPRX currently trades 99.8% from its 52-week high vs VRTX's 91.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | RPRXRoyalty Pharma plc | VRTXVertex Pharmaceut… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.36x | 0.44x |
| 52-Week HighHighest price in past year | $47.34 | $519.68 |
| 52-Week LowLowest price in past year | $29.66 | $362.50 |
| % of 52W HighCurrent price vs 52-week peak | +99.8% | +91.2% |
| RSI (14)Momentum oscillator 0–100 | 75.1 | 61.8 |
| Avg Volume (50D)Average daily shares traded | 3.0M | 1.2M |
Analyst Outlook
Wall Street rates RPRX as "Buy" and VRTX as "Buy". Consensus price targets imply 15.0% upside for VRTX (target: $545) vs 4.5% for RPRX (target: $49). RPRX is the only dividend payer here at 1.42% yield — a key consideration for income-focused portfolios.
| Metric | RPRXRoyalty Pharma plc | VRTXVertex Pharmaceut… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $49.40 | $545.08 |
| # AnalystsCovering analysts | 11 | 55 |
| Dividend YieldAnnual dividend ÷ price | +1.4% | — |
| Dividend StreakConsecutive years of raises | 2 | — |
| Dividend / ShareAnnual DPS | $0.67 | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +1.7% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Jun 20 | Mar 26 | Change |
|---|---|---|---|
| Royalty Pharma plc (RPRX) | 100 | 106.2 | +6.2% |
| Vertex Pharmaceutic… (VRTX) | 100 | 165.51 | +65.5% |
Vertex Pharmaceutic… (VRTX) returned +128% over 5 years vs Royalty Pharma plc (RPRX)'s +21%. A $10,000 investment in VRTX 5 years ago would be worth $22,803 today (including dividends reinvested).
Chart 2Revenue Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Royalty Pharma plc (RPRX) | $1.6B | $2.4B | +48.8% |
| Vertex Pharmaceutic… (VRTX) | $1.7B | $12.0B | +605.1% |
Vertex Pharmaceuticals Incorporated's revenue grew from $1.7B (2016) to $12.0B (2025) — a 24.2% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Royalty Pharma plc (RPRX) | 75.7% | 32.4% | -57.2% |
| Vertex Pharmaceutic… (VRTX) | -6.6% | 32.9% | +600.4% |
Vertex Pharmaceuticals Incorporated's net margin went from -7% (2016) to 33% (2025).
Chart 4P/E Ratio History — 9 Years
| Stock | 2017 | 2025 | Change |
|---|---|---|---|
| Royalty Pharma plc (RPRX) | 19.3 | 21.7 | +12.4% |
| Vertex Pharmaceutic… (VRTX) | 144.1 | 29.6 | -79.5% |
Royalty Pharma plc has traded in a 11x–404x P/E range over 6 years; current trailing P/E is ~27x. Vertex Pharmaceuticals Incorporated has traded in a 21x–144x P/E range over 8 years; current trailing P/E is ~31x.
Chart 5EPS Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Royalty Pharma plc (RPRX) | 1.99 | 1.78 | -10.7% |
| Vertex Pharmaceutic… (VRTX) | -0.46 | 15.32 | +3430.4% |
Vertex Pharmaceuticals Incorporated's EPS grew from $-0.46 (2016) to $15.32 (2025).
Chart 6Free Cash Flow — 5 Years
Royalty Pharma plc generated $2B FCF in 2025 (+23% vs 2021). Vertex Pharmaceuticals Incorporated generated $3B FCF in 2025 (+33% vs 2021).
RPRX vs VRTX: Frequently Asked Questions
9 questions · data-driven answers · updated daily
01Is RPRX or VRTX a better buy right now?
Royalty Pharma plc (RPRX) offers the better valuation at 26.6x trailing P/E (9.7x forward), making it the more compelling value choice. Analysts rate Royalty Pharma plc (RPRX) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — RPRX or VRTX?
On trailing P/E, Royalty Pharma plc (RPRX) is the cheapest at 26.6x versus Vertex Pharmaceuticals Incorporated at 30.9x. On forward P/E, Royalty Pharma plc is actually cheaper at 9.7x.
03Which is the better long-term investment — RPRX or VRTX?
Over the past 5 years, Vertex Pharmaceuticals Incorporated (VRTX) delivered a total return of +128.0%, compared to +21.1% for Royalty Pharma plc (RPRX). A $10,000 investment in VRTX five years ago would be worth approximately $23K today (assuming dividends reinvested). Over 10 years, the gap is even starker: VRTX returned +436.2% versus RPRX's +16.3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — RPRX or VRTX?
By beta (market sensitivity over 5 years), Royalty Pharma plc (RPRX) is the lower-risk stock at 0.36β versus Vertex Pharmaceuticals Incorporated's 0.44β — meaning VRTX is approximately 23% more volatile than RPRX relative to the S&P 500. On balance sheet safety, Vertex Pharmaceuticals Incorporated (VRTX) carries a lower debt/equity ratio of 20% versus 91% for Royalty Pharma plc — giving it more financial flexibility in a downturn.
05Which has better profit margins — RPRX or VRTX?
Vertex Pharmaceuticals Incorporated (VRTX) is the more profitable company, earning 32.9% net margin versus 32.4% for Royalty Pharma plc — meaning it keeps 32.9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: RPRX leads at 65.6% versus 39.1% for VRTX. At the gross margin level — before operating expenses — RPRX leads at 100.0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is RPRX or VRTX more undervalued right now?
On forward earnings alone, Royalty Pharma plc (RPRX) trades at 9.7x forward P/E versus 24.5x for Vertex Pharmaceuticals Incorporated — 14.8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for VRTX: 15.0% to $545.08.
07Which pays a better dividend — RPRX or VRTX?
In this comparison, RPRX (1.4% yield) pays a dividend. VRTX does not pay a meaningful dividend and should not be held primarily for income.
08Is RPRX or VRTX better for a retirement portfolio?
For long-horizon retirement investors, Royalty Pharma plc (RPRX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.36), 1.4% yield). Both have compounded well over 10 years (RPRX: +16.3%, VRTX: +436.2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between RPRX and VRTX?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. RPRX pays a dividend while VRTX does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.